DK1562941T3 - Trans-9,10-dehydroepothilon C og D, analoger deraf og fremstillingsmåder til fremstilling heraf - Google Patents

Trans-9,10-dehydroepothilon C og D, analoger deraf og fremstillingsmåder til fremstilling heraf

Info

Publication number
DK1562941T3
DK1562941T3 DK03768730.8T DK03768730T DK1562941T3 DK 1562941 T3 DK1562941 T3 DK 1562941T3 DK 03768730 T DK03768730 T DK 03768730T DK 1562941 T3 DK1562941 T3 DK 1562941T3
Authority
DK
Denmark
Prior art keywords
trans
dehydroepothilone
analogs
preparation
methods
Prior art date
Application number
DK03768730.8T
Other languages
English (en)
Inventor
Yong Li
Kurt Sundermann
Li Tang
David Myles
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Application granted granted Critical
Publication of DK1562941T3 publication Critical patent/DK1562941T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03768730.8T 2002-11-07 2003-11-07 Trans-9,10-dehydroepothilon C og D, analoger deraf og fremstillingsmåder til fremstilling heraf DK1562941T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42535202P 2002-11-07 2002-11-07
US47374303P 2003-05-27 2003-05-27
PCT/US2003/035411 WO2004043954A2 (en) 2002-11-07 2003-11-07 Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same

Publications (1)

Publication Number Publication Date
DK1562941T3 true DK1562941T3 (da) 2010-04-19

Family

ID=32314587

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03768730.8T DK1562941T3 (da) 2002-11-07 2003-11-07 Trans-9,10-dehydroepothilon C og D, analoger deraf og fremstillingsmåder til fremstilling heraf

Country Status (14)

Country Link
US (2) US20040152708A1 (da)
EP (3) EP1562941B1 (da)
JP (3) JP4641941B2 (da)
KR (2) KR100996996B1 (da)
AT (1) ATE452888T1 (da)
AU (1) AU2003291337B2 (da)
CA (1) CA2505368C (da)
CY (1) CY1110295T1 (da)
DE (1) DE60330703D1 (da)
DK (1) DK1562941T3 (da)
ES (2) ES2436296T3 (da)
PT (1) PT1562941E (da)
SI (1) SI1562941T1 (da)
WO (1) WO2004043954A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
EP1506203B1 (en) 2002-08-23 2007-01-03 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1562941B1 (en) * 2002-11-07 2009-12-23 Kosan Biosciences, Inc. Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same
CN1330648C (zh) * 2002-11-07 2007-08-08 科桑生物科学公司 反式－9,10－脱氢埃坡霉素c和d,其类似物以及制备这些化合物的方法
JP2006523235A (ja) * 2003-03-28 2006-10-12 コーザン バイオサイエンシス インコーポレイテッド 再狭窄を予防するための装置、方法及び組成物
EP1670487A4 (en) * 2003-10-09 2008-05-21 Kosan Biosciences Inc THERAPEUTIC FORMULATIONS
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2686827C (en) 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
DK2118123T3 (da) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabiliserede p53-peptider og anvendelser deraf
WO2008104000A2 (en) 2007-02-23 2008-08-28 Aileron Therapeutics, Inc. Triazole macrocycle systems
ES2610531T3 (es) 2007-03-28 2017-04-28 President And Fellows Of Harvard College Polipéptidos cosidos
WO2008141130A1 (en) * 2007-05-11 2008-11-20 Kosan Biosciences, Inc. Process for the preparation of epothilones
US8030503B2 (en) 2007-05-11 2011-10-04 Kosan Biosciences Incorporated Process for the preparation of epothilones
CA2744088A1 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
CA2776178A1 (en) * 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0706373B1 (en) 1992-03-23 2000-07-19 Georgetown University Liposome encapsulated taxol and a method of using the same
AU6833994A (en) 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
HU226646B1 (en) 1996-03-12 2009-05-28 Pg Txl Company Water soluble pharmaceutical compositions containing taxane derivatives
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
MY125921A (en) 1998-02-05 2006-08-30 Novartis Ag Compositions containing organic compounds
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
DE19907480A1 (de) * 1999-02-11 2000-08-17 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19954229A1 (de) * 1999-11-04 2001-05-10 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
BR0010794A (pt) 1999-05-24 2002-06-04 Sonus Pharma Inc Emulsão-veìculo para drogas com fraca solubilidade
GB9918429D0 (en) 1999-08-04 1999-10-06 Novartis Ag Organic compounds
EP1652926B1 (en) 2000-04-28 2009-09-30 Kosan Biosciences, Inc. Crystalline epothilone d
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US20030176368A1 (en) * 2001-09-06 2003-09-18 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
EP1506203B1 (en) * 2002-08-23 2007-01-03 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) * 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1562941B1 (en) * 2002-11-07 2009-12-23 Kosan Biosciences, Inc. Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same

Also Published As

Publication number Publication date
JP2013213054A (ja) 2013-10-17
ES2436296T3 (es) 2013-12-30
EP1562941A2 (en) 2005-08-17
PT1562941E (pt) 2010-01-25
JP2006510743A (ja) 2006-03-30
US20040152708A1 (en) 2004-08-05
AU2003291337A1 (en) 2004-06-03
CY1110295T1 (el) 2015-01-14
JP5679757B2 (ja) 2015-03-04
CA2505368C (en) 2011-09-20
JP4641941B2 (ja) 2011-03-02
US20090186927A1 (en) 2009-07-23
DE60330703D1 (de) 2010-02-04
ATE452888T1 (de) 2010-01-15
JP2011006480A (ja) 2011-01-13
WO2004043954A3 (en) 2004-11-18
CA2505368A1 (en) 2004-05-27
SI1562941T1 (sl) 2010-05-31
AU2003291337B2 (en) 2010-09-09
KR100966667B1 (ko) 2010-06-29
EP2135867B1 (en) 2013-09-25
EP2135867A1 (en) 2009-12-23
ES2336911T3 (es) 2010-04-19
KR100996996B1 (ko) 2010-11-25
KR20100018075A (ko) 2010-02-16
EP2135868A1 (en) 2009-12-23
KR20050084959A (ko) 2005-08-29
WO2004043954A2 (en) 2004-05-27
EP1562941B1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
DK1562941T3 (da) Trans-9,10-dehydroepothilon C og D, analoger deraf og fremstillingsmåder til fremstilling heraf
IS6699A (is) Kristallað og hreint módafiníl og aðferð við að búa það til
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
BR0211102B1 (pt) método para a produção de uma prótese dentária.
WO2003028576A3 (en) Method and apparatus for dental implants
DE60205413D1 (de) Herstellungsverfahren
ATE509010T1 (de) 2, 4, 6-phenylsubstituierte cyclische ketoenole
NO329883B1 (no) Fremgangsmate for fremstilling av prostaglandiner og analoger derav og av mellomforbindelser, og forbindelser fremstilt derved
NO20040192L (no) Fremgangsmate for a tette et ringrom
WO2004053086A3 (en) Plasmodium falciparum antigens and methods of use
DK1680430T3 (da) Fremgangsmåder til fremstilling af form I af (S)-(+)-Clopidogrel-bisulfat
NO20061125L (no) Fremstilling av somatostatinpeptider
DK1324760T3 (da) Creatin-esterholdige pronæringsstoforbindelser og formuleringer
HUP0401519A2 (hu) Autológ T-sejt-vakcinák
NO20040932L (no) Egnet stigerorsstrekkapparat, metode og system
DK1602360T3 (da) Fremgangsmåde til opnåelse af sneglestrukturer, vaccinesammensætninger, adjuvanser og mellemprodukter dertil
WO2002096799A3 (de) Siliciumsubnitrid, ein verfahren zur dessen hestellung und die verwendung des subnitrids
NO20050769L (no) Fremgangsmate til a innfore en 1,2-dobbelbinding i 3-okso-4-azasteroidforbindelser
ZA200302618B (en) Process for the preparation of cyclic diketones.
MXPA04004526A (es) N-metil-homocisteinas, su uso y metodo para su produccion.
NO20053829L (no) Fremgangsmate og intermediater for fremstilling av olanzapin.
DK1309583T3 (da) Fremgangsmåde til fremstilling af discodermolid og analoge deraf
MXPA03005400A (es) Metodo para preparacion de 11 (12)-pentadecen-15-olidos.
DE60237973D1 (de) Dampfaufwachsverfahren
WO2004096266A8 (en) Improved physical stability of insulin formulations